BioPharmSignal logoBioPharmSignal

Biotech News

ADMA Biologics Announces Third Quarter 2025 Financial Results and Provides Business Update

ADMA Biologics (ADMA)ADMA BiologicsEarnings

3Q 2025 Total Revenue of $134.2 Million, a 12% YoY Increase 3Q 2025 GAAP Net Income of $36.4 Million, a 1% YoY Increase 3Q 2025 Adjusted EBITDA (1) of $58.7 Million, a 29% YoY Increase 3Q 2025 Adjusted Net Income (2) of $38.9 Million, an 8% YoY Increase FDA Lot Release of First Yield-Enhanced

Related news

ADMAADMA Biologics2026-08-05 20:05 EST

ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update

ADMAADMA Biologics2026-05-06 20:05 EST

ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update

STTKShattuck Labs2025-11-06 21:30 EST

Shattuck Labs Reports Third Quarter 2025 Financial Results and Recent Business Highlights

RXRXRecursion2025-11-05 11:30 EST

Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update

ENTXEntera Bio2026-08-07 20:05 EST

Entera Announces Second Quarter 2026 Financial Results and Business Updates

CHRSCoherus BioSciences, Inc.2026-08-05 20:28 EST

Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update

CHRSCoherus BioSciences, Inc.2026-05-11 20:05 EST

Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update

ENTXEntera Bio2026-05-08 20:05 EST

Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs

PHARPharming Group2026-03-12 06:00 EST

Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow

MDXGMiMedx2026-02-25 21:01 EST

MIMEDX Announces Record Fourth Quarter and Full Year 2025 Operating and Financial Results

View all latest news

ADMA Biologics

Plasma-Derived Biologics ADMA Biologics is a vertically integrated U.S. manufacturer and marketer of plasma-derived immunoglobulin therapies for immunodeficient patients and people at risk of infection. ASCENIV ASCENIV is an intravenous immunoglobulin enriched with antibodies against respiratory syncytial virus. It is positioned for...

Recent company news

ADMAADMA Biologics2026-08-05 20:05 EST

ADMA Biologics Reports Second Quarter 2026 Financial Results and Provides Business Update

ADMAADMA Biologics2026-07-29 11:00 EST

ADMA Biologics to Report Second Quarter 2026 Financial Results on August 5, 2026

ADMAADMA Biologics2026-05-06 20:05 EST

ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update

ADMAADMA Biologics2026-05-04 11:00 EST

ADMA Biologics Announces FDA Approval to Expand the Label for ASCENIV™ to Include Pediatric Immune Compromised Patients Two Years of Age and Older

ADMAADMA Biologics2026-04-29 11:00 EST

ADMA Biologics to Report First Quarter 2026 Financial Results on May 6, 2026

Stock data

Close
9.84 USD
Market cap
1.76B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States